

Technical Report No. 53
Guidance for Industry:
Stability Testing to
Support Distribution of
New Drug Products



2011

PDA Stability Testing to Support Distribution of New Drug Products

Erik J. van Asselt, Ph.D., Merck, Sharp & Dohme Corp.

Rafik H. Bishara, Ph.D., (ret.) PDA Pharmaceutical Cold Chain Interest Group Leader

Maryann Gribbin, Johnson & Johnson

Paul Harber, Eli Lilly and Company

Ian G. King, Pfizer Inc.

Arminda O. Montero, Abbott Laboratories (Task Force Co-Leader)

Fabian. S. de Paoli, GlaxoSmithKline plc

Robert H. Seevers, Ph.D., Eli Lilly and Company (Task Force Co-Leader)

David Ulrich, Abbott Laboratories

Sally S. Wong, Merck & Co., Inc.

The content and views expressed in this Technical Report are the result of a consensus achieved by the authorizing Task Force and are not necessarily views of the organizations they represent.

Guidance for Industry: Stability Testing to Support Distribution of New Drug Products

Technical Report No. 53

ISBN: 978-0-939459-34-6

© 2011 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 INTRODUCTION	2	3.5.2 Air Pressure	11
1.1 Purpose	3	3.5.2.1 Surface Shipments	11
1.2 Scope	4	3.5.2.2 Air Shipments	11
2.0 GLOSSARY OF TERMS	5	3.5.3 Humidity	11
3.0 DRUG PRODUCT	6	3.6 Timing of Stability Testing to Support Drug Product Distribution	11
3.1 General	6	3.7 Evaluation and Determination of Time Out of Storage Recommendations and Stability Budget	12
3.2 Standard ICH Testing	6	4.0 BULK DRUG PRODUCT	21
3.3 The Role of Accelerated Testing	7	5.0 CLINICAL TRIAL MATERIALS	22
3.4 Additional Temperature-Stress Studies	7	6.0 REFERENCES	23
3.4.1 Extreme Temperature Studies.....	8		
3.4.2 Temperature-Cycling Studies.....	9		
3.5 Non-Temperature Transportation Hazards.....	10		
3.5.1 Shock (Drop) and Vibration.....	11		

FIGURES AND TABLES INDEX

Table 1.1 Good Distribution Practices Pillars	3	Table 3.7-1 Time Out of Storage for a Frozen Drug Product (i.e., $-20^{\circ}\text{C} \pm 10^{\circ}\text{C}$)	14
Figure 3.1 Distribution Model	6	Table 3.7-2 Example Stability Budget for a Frozen Drug Product	15
Table 3.2 Standard Stability Testing Conditions for Drug Product	7	Table 3.7-3 Time Out of Storage for a Refrigerated Drug Product	16
Table 3.4.1-1 Example Extreme Excursion Studies for Pharmaceutical Drug Product.....	8	Table 3.7-4 Example Stability Budget for a Refrigerated Drug Product	17
Table 3.4.1-2 Example Extreme Excursion Studies for Biological Drug Product.....	8	Table 3.7-5 Time Out of Storage for a Room Temperature Drug Product.....	18
Table 3.4.2-1 Example Temperature-Cycling Studies for Pharmaceutical Drug Product	9	Table 3.7-6 Example Stability Budget for a Room Temperature Drug Product.....	20
Table 3.4.2-2 Example Temperature-Cycling Studies for Biological Drug Product.....	10		